EMADINE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMADINE is an ophthalmic solution approved in 1997 for eye conditions. The specific indication and mechanism of action are not publicly documented in available sources. It is administered as eye drops for topical ocular use.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure; expect team restructuring and focus shift toward lifecycle extension or managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EMADINE currently shows zero linked job postings, reflecting its mature LOE-approaching status. Career opportunities on this product are limited and likely focused on defensive commercial strategies rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on EMADINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.